A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-20. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Willes (1963), former president of the Federal Reserve Bank of Minneapolis, CEO and Publisher of Los Angeles Times and Deseret Management Corporation Harry Saal (1963), co-founder of Network General Corporation, developer of the Sniffer Steven Clifford (1964), former CEO of King Broadcasting Company and National Mobile Television Arthur Cutler (1965), restaurateur, founder of Carmine's, Ollie's, and owner of Murray's Sturgeon Shop Ed Goodgold (1965), music industry executive and former manager of Sha Na Na, coined the term "trivia" Michael Gould (1966), former CEO of Bloomingdale's Julian Geiger (1967), former CEO of Aéropostale and current CEO of Crumbs Bake Shop Richard Sackler (1967), billionaire chairman and president of Purdue Pharma known for the development of Oxycontin Denny Greene (1971), former executive at Columbia Pictures, professor at University of Dayton School of Law, and member of Sha Na Na Mark E. Kingdon (1971), hedge fund manager, president of Kingdon Capital Management Philip L. Milstein (1971), former chairman and CEO of Emigrant Savings Bank, son of billionaire real estate developer Seymour Milstein Christopher M. Jeffries (1972), real estate developer, former husband of Princess Yasmin Aga Khan Marc Porat (1972), entrepreneur in information technology and sustainable materials; co-founder of General Magic John R. Eckel Jr. (1973), founder, CEO and chairman of Copano Energy Finbarr O'Neill (1973), former CEO of J.D. Power Fred Seibert (1973), TV producer and first creative director of MTV Robert B.
Performing differential cell counts on body fluids, such as serous, synovial and cerebrospinal fluid Cytopathology examination of liquid specimens such as body fluids and fine needle aspirates Gram staining of fluid specimens for identification of microorganisms
=== Directed evolution === A primary goal of protein engineering is the design of novel peptides or proteins with a desired structure and chemical activity. Because our knowledge of the relationship between primary sequence, structure, and function of proteins is limited, rational design of new proteins with engineered activities is extremely challenging. In directed evolution, repeated cycles of genetic diversification followed by a screening or selection process, can be used to mimic natural selection in the laboratory to design new proteins with a desired activity. Several methods exist for creating large libraries of sequence variants. Among the most widely used are subjecting DNA to UV radiation or chemical mutagens, error-prone PCR, degenerate codons, or recombination. Once a large library of variants is created, selection or screening techniques are used to find mutants with a desired attribute. Common selection/screening techniques include FACS, mRNA display, phage display, and in vitro compartmentalization. Once useful variants are found, their DNA sequence is amplified and subjected to further rounds of diversification and selection. The development of directed evolution methods was honored in 2018 with the awarding of the Nobel Prize in Chemistry to Frances Arnold for evolution of enzymes, and George Smith and Gregory Winter for phage display.
Sources: en.wikipedia.org
== Other == Jane Allen Campbell (1865–1938), American heiress and Italian princess of San Faustino Paul Cushing Child (1902–1994), husband of chef Julia Child, who introduced his wife to fine cuisine, which began her legendary career Victor E. Engstrom (1914–2000), philatelist Vladimir Guryev and Lydia Guryev, a.k.a. Richard and Cynthia Murphy, arrested in their Montclair home June 2010 by FBI; admitted in court to being agents of the Russian Federation and pleaded guilty to conspiracy to act as unregistered agents; expelled with eight others in a prisoner exchange with Russia Florence Merriam Johnson (c. 1876–1954), American Red Cross nurse during World War I, received Florence Nightingale Medal Isaac Newton Lewis (1858–1931), soldier and inventor who created the Lewis gun Mizkif (born 1995), Twitch streamer Pearl Grigsby Richardson (1896–1983), educator and clubwoman
(2026) reconstruct the environment of Pleistocene gazelles and Persian fallow deer from the Mughr el-Hamamah site (Jordan) on the basis of isotopic analysis of their teeth, interpret their findings as indicative of conditions that were favorable for human occupations during a humid phase of the Last Glacial cycle, and estimate that the hunting area of Early Upper Paleolithic humans from the site covered ∼36 square kilometers. García-Morato et al. (2026) review the fossil record of small-bodied mammals from Middle to Later Stone Age sites in South Africa, and report evidence of impact of site-specific ecological factors on the composition of the studied assemblages. Sawada et al. (2026) interpret burned bone fragments from the terminal Paleolithic strafa from the Fukui Cave (Japan) as more likely to be evidence of human exploitation of medium-sized artiodactyls than evidene of exploitation of large mammals that became extinct in the Pleistocene. Evidence indicating that deposition of sediments preserving bones of mammals (mostly mammoths) at The Mammoth Site (South Dakota, United States) happened during Marine Isotope Stages 6 and 7 is presented by Mahan et al. (2026). Pym et al. (2026) reconstruct changes of late Pleistocene megafaunal populations from the Isthmus of Panama on the basis of the study of spores of coprophilous fungi from sediments of the La Yeguada lake, providing evidence of three distinct phases of decline and recovery coinciding with shifts in vegetation composition. Asevedo et al.
In 2010, the International Fragrance Association published a list of 3,059 chemicals used in 2011 based on a voluntary survey of its members, identifying about 90% of the world's production volume of fragrances.
== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
Sources: en.wikipedia.org
=== Amino acid biosynthesis === All amino acids are formed from intermediates in the catabolic processes of glycolysis, the citric acid cycle, or the pentose phosphate pathway. From glycolysis, glucose 6-phosphate is a precursor for histidine; 3-phosphoglycerate is a precursor for glycine and cysteine; phosphoenol pyruvate, combined with the 3-phosphoglycerate-derivative erythrose 4-phosphate, forms tryptophan, phenylalanine, and tyrosine; and pyruvate is a precursor for alanine, valine, leucine, and isoleucine. From the citric acid cycle, α-ketoglutarate is converted into glutamate and subsequently glutamine, proline, and arginine; and oxaloacetate is converted into aspartate and subsequently asparagine, methionine, threonine, and lysine.
In North America, the 323 saloon became the Protegé, while the 323 hatchback kept its name. There, and in the Philippines, base (SE/DX), 4WD and top-line LX models were available. The 1990 base model has the SE name and uses the B8 1.8 L SOHC engine that has 16 valves and hydraulic lifters. In 1991, the base model name was changed to "DX". 4WD models existed for the 1990 and 1991 model years, with the SOHC engine and rear disc brakes. The LX version of the Protegé included a 1.8 L DOHC 16-valve BP engine producing 125 hp (93 kW; 127 PS). LX models also have power windows and door locks and 14-inch wheels. Vented front and solid rear disc brakes, larger front brakes, larger clutch, equal-length driveshafts, dual outlet muffler, body-color door handles and mirrors, fold-down rear center armrest, driver's vanity mirror, and larger stabilizer bars. A sunroof and 14-inch aluminum alloy wheels were options on LX models. The Protegé nameplate was also applied for 323 saloon in Brazil, which was really similar to the Canadian market specification. However, only a fuel injected 1.8 L SOHC engine was offered there. BG models that were assembled in New Zealand came with glass headlights instead of plastic, and a 240 km/h speedometer. In Thailand, the 323 saloon was initially offered in a single unnamed trim with a carbureted 1.6 L SOHC engine as the sole option. The facelifted model was divided into two levels: the 1.3i and 1.6i LX, and the better-equipped 1.6i GLX. All engines featured fuel injection, and the latter came with a 4-speed automatic transmission as an option.
==== Electroporation ==== Electroporation is a method that uses high voltage to create pores in the membranes of mammalian cells. By pulsing with electricity, local areas of the cell membrane transiently destabilize and DNA can then enter the cell. At appropriate field strengths, damage to the host cell in minimal. This technique can be used for both short-term and long-term transfectants. It is also effective with almost any tissue type and has displayed high levels of gene delivery with an increase in the distribution of cells expressing the DNA.
Having considered the data provided, and other relevant information available in scientific literature, the SCCS cannot conclude on the safety of the hydroxyapatite composed of rod–shaped nanoparticles for use in oral-care cosmetic products at the maximum concentrations and specifications given in this Opinion. This is because the available data/information is not sufficient to exclude concerns over the genotoxic potential of HAP-nano. The European Commission's Scientific Committee on Consumer Safety (SCCS) reissued an updated opinion in 2023, where it cleared rod-shaped nano hydroxyapatite of concerns regarding genotoxicity, allowing consumer products to contain concentrations of nano hydroxyapatite as high as 10% for toothpastes and 0.465% for mouthwashes. However, it warns of needle-shaped nano hydroxyapatite and of inhalation in spray products. It stated:
=== Aging === There is a strong association between SIRT3 alleles and longevity in males. Activation of SIRT3 inhibits the apoptosis leading to age-related macular degeneration. SIRT3 induced mitophagy, inhibiting cell death, and thus could be used to treat neurodegenerative diseases.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.